Tharimmune (NASDAQ:THAR) and ObsEva (NASDAQ:OBSV) Critical Analysis

Tharimmune (NASDAQ:THAR) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Tharimmune and ObsEva, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	0	0	1	1	3.50
ObsEva	0	0	0	0	0.00

Tharimmune presently has a consensus price target of $17.00, suggesting a potential upside of 794.74%. Given Tharimmune’s stronger consensus rating and higher probable upside, analysts plainly believe Tharimmune is more favorable than ObsEva.

Profitability

This table compares Tharimmune and ObsEva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-167.63%	-130.18%
ObsEva	N/A	-416.36%	-92.01%

Valuation and Earnings

This table compares Tharimmune and ObsEva”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$9.32 million	N/A	N/A
ObsEva	$20.11 million	0.00	-$58.38 million	($0.92)	N/A

Tharimmune has higher earnings, but lower revenue than ObsEva.

Risk and Volatility

Tharimmune has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

Institutional and Insider Ownership

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 2.4% of Tharimmune shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Tharimmune beats ObsEva on 7 of the 11 factors compared between the two stocks.

About Tharimmune

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.